ARTICLE | Finance
Why liver disease newco Alentis is aiming for one of largest Swiss A rounds
BioMedPartners, BB Pureos Bioventures lead $12M first close for Basel start-up
April 30, 2019 12:01 AM UTC
Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the largest series A for a Swiss biotech since 2015.
Founded in the BaseLaunch incubator in Basel, Alentis Therapeutics AG announced it raised CHF12.5 million ($12.3 million) in a series A round co-led by BioMedPartners and BB Pureos Bioventures. Other new investors included BPI France, German High-Tech Gründerfonds (HTGF) and Schroder Adveq...